Pharmaceuticals
Starpharma signs new DEP® agreement with MSD
MELBOURNE, Australia, Aug. 10, 2022 /PRNewswire/ -- Australian biotechnology company Starpharma today announced it has signed a new DEP® Research Agreement with MSD, the trade name of Merck Sharp & Dohme LLC,Rahway, NJ, USA. This new DEP® program will generate and evaluate additional DEP® Antibod...
2022-08-10 15:29
1665
Bridge Biotherapeutics Presents Promising Interim Clinical Study Results from Phase 1 Study of BBT-176 at WCLC 2022
* The study confirmed preliminary efficacy and safety of BBT-176 along with its treatment responses in advanced NSCLC patients * A patient with the C797S triple mutation showed up to 53 percent reduction in EGFR mutant allelic change VIENNA and SEONGNAM, South Korea, Aug. 9, 2022 /PRNewswire/...
2022-08-10 11:43
1581
MedAlliance SELUTION SLR Receives Second FDA IDE Approval
GENEVA, Aug. 10, 2022 /PRNewswire/ -- SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of occlusive disease of the superficial femoral artery (SFA). ...
2022-08-10 10:00
2536
Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Moderate-to-severe Plaque Psoriasis Met Primary Endpoint
SAN FRANCISCO and SUZHOU, China, Aug. 10, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
2022-08-10 08:00
2834
Merck Becomes One of the First CDMOs to Provide Full Viral Vector Offering with Launch of VirusExpress® 293 Adeno-Associated Virus Production Platform
* Reduces process development time by an estimated 40 percent * Enables biopharmaceutical companies to increase the speed to clinical manufacturing * Adds to company's best-in-class VirusExpress® Lentiviral Production Platform DARMSTADT,Germany, Aug. 9, 2022 /PRNewswire/ -- Merck, a leading s...
2022-08-09 20:00
2670
Novaliq submits New Drug Application seeking approval for first-of-a-kind Dry Eye Disease Treatment CyclASol®
HEIDELBERG, Germany, and CAMBRIDGE, MA, Aug. 9, 2022 /PRNewswire/ -- Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced the submission of a New Drug Application (NDA) to the U.S. Food and...
2022-08-09 19:00
1766
Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in China
SUZHOU, China, Aug. 9, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment and dosing of 92 subjec...
2022-08-09 17:00
1813
Harbour BioMed to Announce 2022 Interim Results on August 31, 2022
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 9, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142) announced that it will report financial results for the first half year endedJune 30, 2022, on Wednesday, August 31, 2022. The Company will host an English virtual ...
2022-08-09 15:00
1565
Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-004
SAN DIEGO, SHANGHAI and HONG KONG, Aug. 9, 2022 /PRNewswire/ -- Inmagene
Biopharmaceutical ("Inmagene
2022-08-09 12:00
1548
Sciwind Biosciences Reports Positive Interim Results from Phase 1c/2a Clinical Trial of XW003 (Ecnoglutide) in Overweight and Obese Adult Volunteers in China
* Mean body weight loss of 9.6% and 9.0% in participants receiving 1.8 mg and 2.4 mg XW003 for 14 weeks, respectively * Up to 72.4% of participants achieved weight loss of at least 5% at week 14 * XW003 was safe and well tolerated with gastrointestinal side effects as the most commonly repor...
2022-08-09 08:00
2119
FRONTIER BIOTECHNOLOGIES ANNOUNCES POSITIVE PHASE 1 RESULTS OF ITS FIRST CORONAVIRUS MAIN PROTEASE (MPRO) SMALL MOLECULE INHIBITOR, LAYING FOUNDATION FOR THE TREATMENT OF ACUTE AND LONG COVID
* FB2001 (Bofutrelvir) is a Coronavirus Mpro inhibitor, which exhibited potent anti-SARS-CoV-2 activityin vitro and in vivo * Phase 1 results show FB2001 to be generally safe and well tolerated. No significant difference was observed between Chinese and American populations. Single-agent anti...
2022-08-09 00:00
2780
BGI Ranks No. 1 among APAC and China Life Science Corporations for Seven Consecutive Years: 2022 Nature Index Annual Tables Revealed
SHENZHEN, China, Aug. 8, 2022 /PRNewswire/ -- BGI has topped the Asia Pacific andChina life science corporate institution ranking table for the seventh year running, released in the 2022 Nature Index Annual Tables. With a 19 percent increase in its adjusted share metric, BGI ranked eighth among g...
2022-08-08 22:00
2019
PNAS Published Preclinical Results of Harbour BioMed's Next-Generation Fully Human Heavy-chain Antibody Porustobart
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 8, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142) announced that the preclinical results of porustobart (HBM4003,or the HCAb 4003-2 in the research paper), a next-generation fully human heavy-chain antibody with a ...
2022-08-08 17:43
1314
The world's leading brand of fashionable colored masks officially launches on Amazon on August 8th from CSD, a professional disposable medical supplies manufacturer in Taiwan
TAIPEI, Aug. 8, 2022 /PRNewswire/ -- People dress according to mood, occasion,
and necessity - and the mask, which inherently occupies half of the face, is an
indispensable fashion accessory. On August 8th, COLO, a fashionable mask brand
with colorful designs, will debut onAmazon
2022-08-08 13:04
1496
Xinhua Silk Road: E. China's Wuxi city steps up biomedical industry development
BEIJING, Aug. 8, 2022 /PRNewswire/ -- The 2022 Taihu Bay Future Healthcare Conference held Thursday in Wuxi City in eastChina's Jiangsu Province witnessed the launch of Wuxi Intellectual Property Protection Center with 52 biomedical projects contracted, involving a total of more than30 billion yu...
2022-08-08 12:24
2384
BIO Asia-Taiwan 2022 concludes, marking another successful edition of the region's biggest bioindustry-focused conference and exhibition
Exhibition visitors surpass 100,000 people over 4 days BIO Asia–Taiwan success a testament to Taiwan's booming biotechnology industry TAIPEI, Aug. 8, 2022 /PRNewswire/ -- BIO Asia–Taiwan 2022, held at the TaiNEX 2 Exhibition Center, Nangang,Taipei, from 27-31 July, came to a successful conclusio...
2022-08-08 10:00
4910
ImmVira's Brand New oHSV Product MVR-C5252 Targeting Malignant Glioma Obtained FDA's Orphan Drug Designation
SHENZHEN, China, Aug. 7, 2022 /PRNewswire/ -- On August 1, 2022, U.S. time,
ImmVira's brand new oncolytic herpes simplex virus ("oHSV") product MVR-C5252
targeting Malignant Glioma has obtained Orphan Drug Designation ("ODD") from
U.S. Food and Drug Administration ("FDA").
2022-08-08 08:30
1438
Ascletis Announces First Patient Dosed in the U.S. Phase I Clinical Trial of Oral PD-L1 Small Molecule Inhibitor Prodrug ASC61 for Treatment of Advanced Solid Tumors
--ASC61 is an in-house developed oral PD-L1 small molecule inhibitor prodrug that showed significant antitumor efficacy in preclinical studies as a single agent in multiple animal models --ASC61-A treatment induced secretion of IFNγ in a concentration dependent manner with an EC50 of 2.86 nM. Ma...
2022-08-08 08:10
2147
CStone presents updated results of a registrational study of sugemalimab in patients with stage III NSCLC via oral presentation at WCLC 2022
* GEMSTONE-301 study result was presented at IASLC 2022 World Conference on Lung Cancer. In addition, the leading Principal Investigator ProfessorYi-Long Wu was invited to highlight key data in a press conference * In the final progression-free survival analysis, sugemalimab showed sustained ...
2022-08-08 08:08
2065
Transcenta Announces the Appointment of Dr. Caroline Germa as Executive Vice President, Global Medicine Development and Chief Medical Officer
SUZHOU, China, Aug. 8, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics,announces the appointment of Dr. ...
2022-08-08 08:00
2173
Week's Top Stories
Most Reposted
Multiple achievements made in China-Hungary BRI conference
[Picked up by 317 media titles]
2024-05-03 06:59
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 295 media titles]
2024-04-30 10:11
Xinhua president, Hungarian economy minister vow to bolster media cooperation
[Picked up by 287 media titles]
2024-05-03 06:25TAILG Makes Grand Appearance at 2024 Asiabike Jakarta, Aiming to Set the Benchmark in Indonesia
[Picked up by 262 media titles]
2024-05-02 01:21
Chinese new energy industry contributes to global green, low-carbon transition
[Picked up by 253 media titles]
2024-04-30 15:13Most Read
/C O R R E C T I O N -- Addverb/
2024-05-03 20:26
11500
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
2024-04-30 10:11
7538
Multiple achievements made in China-Hungary BRI conference
2024-05-03 06:59
7400
Xinhua president, Hungarian economy minister vow to bolster media cooperation
2024-05-03 06:25
6957
